Am­gen wants in on obe­si­ty. But it's still work­ing on rare dis­ease, too

Am­gen tout­ed its rare dis­ease strat­e­gy on Thurs­day, high­light­ing the fi­nan­cial po­ten­tial of both cur­rent block­busters and oth­er drugs in its pipeline.

The spot­light on rare dis­eases fol­lows the com­ple­tion of its $28 bil­lion ac­qui­si­tion of Hori­zon Ther­a­peu­tics in 2023. Am­gen is now work­ing to in­te­grate Hori­zon and its pipeline fol­low­ing the re­cent ad­di­tion of rare dis­ease as the fourth pil­lar of its R&D fo­cus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER